Loading organizations...

Obsidian Therapeutics is a technology company.
Obsidian Therapeutics has raised $330.5M across 3 funding rounds.
Obsidian Therapeutics has raised $330.5M in total across 3 funding rounds.
Obsidian Therapeutics is pioneering engineered cell and gene therapies to deliver transformative outcomes for patients, utilizing its proprietary cytoDRiVE® platform.
Obsidian Therapeutics has raised $330.5M in total across 3 funding rounds.
Obsidian Therapeutics's investors include Irina Margine, Ph.D., Atlas Venture, Bristol Myers Squibb, Deep Track Capital, Foresite Capital, Janus Henderson Investors, Logos Capital, Ray Camahort, Paradigm BioCapital, RA Capital Management, RTW Investments, Samsara BioCapital.
Obsidian Therapeutics is a biotechnology company developing engineered tumor infiltrating lymphocyte (TIL) therapies for solid tumor malignancies, primarily using its proprietary cytoDRiVE® platform to create controllable cell therapies that enhance anti-tumor activity.[1][2][3] It serves patients with advanced cancers like metastatic melanoma, addressing limitations in traditional TIL therapies by enabling tunable protein expression via FDA-approved small molecules, with its lead program OBX-115 in ongoing clinical trials showing positive data as of June 2025.[1][3][5] The company demonstrates strong growth momentum through recent clinical advancements, multiple 2025 conference presentations, and expansion of its Bedford, MA manufacturing facility, supported by a collaborative team across Cambridge and Bedford locations.[1][5]
Obsidian Therapeutics emerged from pioneering research in destabilizing domains (DD) by its scientific founder, Professor Thomas Wandless, a leader in chemical and systems biology, which forms the basis of its cytoDRiVE® technology for controlling protein activity in cells.[2] The company was co-founded by Michael Gilman, who serves as CEO, bringing expertise in biotech leadership.[6] Key early figures include board chair Maria Fardis, Ph.D., with over 20 years in scientific management across public and private firms, and scientific advisors like Michael Briskin, former discovery head at Jounce Therapeutics, and immunotherapy expert with global patents.[4] Pivotal moments include advancing OBX-115 into multicenter trials for advanced melanoma and reporting positive clinical data at the 2025 ASCO meeting, building on preclinical successes presented at ASGCT and AACR.[5]
Obsidian's edge lies in its cytoDRiVE® platform, which uses drug-responsive domains (DRDs) to regulate therapeutic proteins with non-immunosuppressive, FDA-approved small molecules, allowing precise control—proteins stabilize with the drug and degrade without it via cellular quality control.[2][3] Key strengths include:
Obsidian rides the cell and gene therapy wave, specifically advancing TIL therapies amid surging demand for solid tumor immunotherapies, where traditional CAR-T struggles with heterogeneity and exhaustion.[1][3] Timing aligns with 2025 clinical milestones, including ASCO data validating tunable approaches, fueled by market forces like FDA small-molecule approvals and biotech funding resurgence post-2023 lows.[5] It influences the ecosystem by pioneering "pharmacologic operating systems" for cells, potentially standardizing controllable edits and inspiring hybrid therapies combining immunotherapy with metabolic/bioengineering insights from advisors.[2][4]
Obsidian is poised for Phase 2 expansion of OBX-115 and broader cytoDRiVE® applications (e.g., other solid tumors, gene editing), with 2025 data de-risking its platform amid rising investor interest in controllable cell therapies.[5] Trends like AI-optimized protein design and combo regimens with checkpoints will shape progress, potentially evolving Obsidian into a multi-product leader influencing precision oncology. This positions it to transform TIL from niche to frontline, delivering on its promise of engineered breakthroughs for unmet cancer needs—much like its namesake volcanic glass, forged under pressure into a sharp tool for patients.[4]
Obsidian Therapeutics has raised $330.5M across 3 funding rounds. Most recently, it raised $160.5M Series C in April 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 3, 2024 | $160.5M Series C | Irina Margine, Ph.D. | Atlas Venture, Bristol Myers Squibb, Deep Track Capital, Foresite Capital, Janus Henderson Investors, Logos Capital, Ray Camahort, Paradigm BioCapital, RA Capital Management, RTW Investments, Samsara BioCapital, Surveyor Capital, TCGX, T. Rowe Price Associates, Woodline Partners |
| Sep 1, 2021 | $120.0M Series B | The Column Group | Atlas Venture, F-Prime Capital Partners, Amgen Ventures, Bristol Myers Squibb, Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, RA Capital Management, Samsara BioCapital, Soleus Capital, Surveyor Capital, Vertex, Vertex Ventures HC |
| Dec 1, 2017 | $50.0M Series A | Blake Byers | Atlas Venture, F-Prime Capital Partners, Alexandria Venture Investments, Gladys Nunez, ShangPharma Investment Group, Karen Hong, Carolyn Ng |